-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
(Health Times network end of the reporter Kong Tianqiu)
. The official guidance of the tumor drug super specification is here! Recently, the Guangdong Pharmaceutical Society released the "SuperDrug Specification Stake Catalog (2019 Edition)," of which nearly 30 drugs and anti-tumor-related.
the drug specification is after a rigorous clinical trial, and is the drug supervision and administration department of the approval of the drug, has an important legal basis for the use of drugs, the Chinese Academy of Medical Sciences Oncology Hospital, deputy director of oncology medicine physician Liu Peng told the Health Times. But in clinical, due to the manufacturer's declaration or approval department approval has a certain lag, especially tumor drugs, over-the-top drug is sometimes inevitable.
" drug overspecification is not without evidence-based medical evidence. Liu Peng said that the over-the-top drug use is not a personal judgment given by doctors, but there is a sufficient basis for clinical trials, many are relevant guidelines or learn to recommend, doctors will arrange for patients to take medication. The vast majority of over-the-counter drug administration hospitals have specific process requirements, generally for the hospital pharmacy department to apply, approved by the Pharmaceutical Association and ethics council, in the medical department for the record, doctors can use.
the current state has not yet for the over-the-top drug use of separate legislation, but the Health Times reporter learned that the Guangdong Pharmaceutical Society in 2014 issued a red-headed document "on the issuance of <> notice", pointed out that the over-the-top drug should meet five conditions:
(1) in the impact on the quality of life of patients or life-threatening circumstances, there is no reasonable alternative medicine;
(2) the purpose of drug use is not experimental research;
(3) have reasonable evidence of medical practice;
(4) approved by the Hospital Pharmaceutical Management and Pharmacology Committee (or the Pharmaceutical Management Committee) and the Ethics Committee; and
(5) protect the patient's right to know.
Health Times reporter according to the Guangdong Pharmaceutical Society" "SuperDrug Specification Drug Catalog (2019 edition)" to organize the relevant tumor drugs superdrug specification content.
.